Clinical Trials for Non-Small Cell Lung Cancer

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for roughly 85% of all lung cancer diagnoses, according to the American Cancer Society. Over the past decade, treatment for NSCLC has been transformed by targeted therapies and immunotherapy -- breakthroughs that came directly from clinical trials.

That research is still happening. Trials today are studying treatments for specific mutations, combinations of immunotherapy with other agents, and strategies for people whose cancer has progressed on first-line therapy. If your treatment has been denied or if your current therapy is no longer working, a clinical trial may offer a real path forward.

What Types of Trials Are Available?

Targeted therapy trials are among the most important for NSCLC. If your tumor has been tested for mutations like EGFR, ALK, ROS1, KRAS G12C, BRAF V600E, MET exon 14, or others, there are trials designed specifically for your mutation profile. These precision medicine approaches have produced some of the most dramatic results in modern oncology. Immunotherapy trials study checkpoint inhibitors -- including PD-1 and PD-L1 inhibitors -- alone and in combination with chemotherapy, targeted therapy, or other immunotherapy agents. Pembrolizumab (Keytruda) was itself once investigational; trials today are building on and beyond it. Early-stage trials study whether surgery, radiation, or targeted therapy in earlier-stage NSCLC can reduce recurrence. Resistance mechanism trials are designed for people whose cancer has progressed after initial treatment, studying new approaches to overcoming drug resistance.

Search ClinicalTrials.gov for currently recruiting NSCLC trials.

Am I Eligible?

Eligibility for NSCLC trials depends heavily on:

- Your specific cancer subtype (adenocarcinoma, squamous cell, large cell)

- Stage at diagnosis and current disease extent

- Tumor biomarker and mutation testing results (next-generation sequencing is often required)

- PD-L1 expression level

- Prior treatment history -- including lines of therapy tried and response achieved

- Performance status (ECOG score, a measure of functional ability)

- No brain metastases (some trials include it; many do not)

Biomarker testing is particularly important. If your tumor has not been tested with next-generation sequencing (NGS), ask your oncologist whether that testing should happen before exploring trials -- it dramatically expands your options.

Talk to your oncologist before making any decisions about your treatment.

What If My Insurance Denied My Medication?

Insurance denials for NSCLC treatments -- including checkpoint inhibitors like pembrolizumab (Keytruda) and targeted therapies -- can happen even when the treatment aligns with guideline-recommended care. If your oncologist prescribed a therapy and your insurer denied it, you have the right to appeal.

NCI-designated cancer centers are required to offer clinical trial access. If you are not near one, many trials have multiple sites, and the trial coordinators can help identify the closest one.

A clinical trial may offer access to a treatment that is similar to, or more advanced than, what your insurance denied.

Ellen can help you figure out your next step. Start with Ellen →

Frequently Asked Questions

Are clinical trials for non-small-cell lung cancer free?

In most cases, yes. Trial sponsors (pharmaceutical companies, universities, or the NIH) cover the cost of the experimental treatment. You may still have costs for routine care — like doctor visits or standard tests — depending on your insurance. Always ask the trial coordinator what costs you might be responsible for before enrolling.

How do I find non-small-cell lung cancer trials near me?

The best place to start is ClinicalTrials.gov, the official registry of all trials in the US. Search by condition name and filter by your location. Your specialist can also help identify trials at academic medical centers in your region.

Can I join a trial after being denied Keytruda?

Yes, and in many cases a denial can actually make you a stronger candidate — trials often enroll patients who have not responded to or cannot access standard treatments. Talk to your doctor about whether your denial history makes you eligible for open trials studying Keytruda or similar medications.